Prognostic factors in MNU and DMBA-induced mammary tumors in female rats

Pathology Research and Practice

Volumn 213, Issue 5, 2017, Pages 441-446

  Alvarado, Antonieta ^a,b,c   Lopes, Ana C ^d,e   Faustino Rocha, Ana I ^b,c,f   Cabrita, António M S ^d   Ferreira, Rita ^f   Oliveira, Paula A ^b,c   Colaço, Bruno ^b,c  

^a UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e University School Vasco da Gama   (Portugal)

^f UNIVERSITY OF AVEIRO   (Portugal)

Author keywords

Chemical carcinogen; Estrogen receptor; Ki 67; Mammary cancer; Progesterone receptor; Sprague Dawley

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ESTROGEN RECEPTOR ALPHA; KI 67 ANTIGEN; METHYLNITROSOUREA; PROGESTERONE RECEPTOR; CARCINOGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST TUMOR; CANCER PROGNOSIS; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MITOSIS RATE; NONHUMAN; PAPILLARY CARCINOMA; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT; TREATMENT RESPONSE; TUMOR VOLUME; ANIMAL; CARCINOMA; CHEMICALLY INDUCED; DISEASE MODEL; EXPERIMENTAL MAMMARY NEOPLASM; HUMAN; METABOLISM; PATHOLOGY; PROGNOSIS;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BREAST NEOPLASMS; CARCINOGENS; CARCINOMA; DISEASE MODELS, ANIMAL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; PROGNOSIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROGESTERONE;

EID: 85014795896     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2017.02.014     Document Type: Article

References (31)

1. [1] Imaoka, T., Nishimura, M., Doi, K., Tani, S., Ishikawa, K., Yamashita, S., Ushijima, T., Imai, T., Shimada, Y., Molecular characterization of cancer reveals interactions between ionizing radiation and chemicals on rat mammary carcinogenesis. Int. J. Cancer 134 (2014), 1529–1538.
2. [2] Ariazi, J.L., Haag, J.D., Lindstrom, M.J., Gould, M.N., Mammary glands of sexually immature rats are more susceptible than those of mature rats to the carcinogenic, lethal, and mutagenic effects of N-nitroso-N-methylurea. Mol. Carcinog. 43 (2005), 155–164.
3. [3] Sharma, D., Smits, B.M., Eichelberg, M.R., Meilahn, A.L., Muelbl, M.J., Haag, J.D., Gould, M.N., Quantification of epithelial cell differentiation in mammary glands and carcinomas from DMBA- and MNU-exposed rats. PLoS One, 6, 2011, e26145.
4. [4] Alvarado, A., Faustino-Rocha, A.I., Ferreira, R., Mendes, R., Duarte, J.A., Pires, M.J., Colaco, B., Oliveira, P.A., Prognostic factors in an exercised model of chemically-induced mammary cancer. Anticancer Res. 36 (2016), 2181–2188.
5. [5] Faustino-Rocha, A.I., Gama, A., Oliveira, P.A., Alvarado, A., Neuparth, M.J., Ferreira, R., Ginja, M., Effects of lifelong exercise training on mammary tumorigenesis induced by MNU in female Sprague-Dawley rats. Clin. Exp. Med., 2016, 10.1007/s10238-016-0419-0.
6. [6] Lopes, A.C., Cova, T.F., Pais, A.A., Pereira, J.L., Colaco, B., Cabrita, A.M., Improving discrimination in the grading of rat mammary tumors using two-dimensional mapping of histopathological observations. Exp. Toxicol. Pathol. 66 (2014), 73–80.
7. [7] Faustino-Rocha, A.I., Ferreira, R., Oliveira, P.A., Gama, A., Ginja, M., N-Methyl-N-nitrosourea as a mammary carcinogenic agent. Tumor Biol. 36 (2015), 9095–9117.
8. [8] Lu, J., Jiang, C., Mitrenga, T., Cutter, G., Thompson, H.J., Pathogenic characterization of 1-methyl-1-nitrosourea-induced mammary carcinomas in the rat. Carcinogenesis 19 (1998), 223–227.
9. [9] Budan, F., Varjas, T., Nowrasteh, G., Varga, Z., Boncz, I., Cseh, J., Prantner, I., Antal, T., Pazsit, E., Gobel, G., Bauer, M., Gracza, T., Perjesi, P., Ember, I., Gyongyi, Z., Early modification of c-myc, Ha-ras and p53 expressions by N-methyl-N-nitrosourea. In Vivo 22 (2008), 793–797.
10. [10] Juhasz, K., Gombos, K., Szirmai, M., Gocze, K., Wolher, V., Revesz, P., Magda, I., Sebestyen, A., Nemeth, A., Ember, I., Very early effect of DMBA and MNU on microRNA expression. In Vivo 27 (2013), 113–117.
11. [11] O'Day, E., Lal, A., MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res., 12, 2010, 201.
12. [12] Kariagina, A., Aupperlee, M.D., Haslam, S.Z., Progesterone receptor isoform functions in normal breast development and breast cancer. Crit. Rev. Eukaryot. Gene Expr. 18 (2008), 11–33.
13. [13] Obr, A.E., Edwards, D.P., The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol. Cell. Endocrinol. 357 (2012), 4–17.
14. [14] Hanstein, B., Djahansouzi, S., Dall, P., Beckmann, M.W., Bender, H.G., Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Eur. J. Endocrinol. 150 (2004), 243–255.
15. [15] Lannigan, D.A., Estrogen receptor phosphorylation. Steroids 68 (2003), 1–9.
16. [16] Lange, C.A., Yee, D., Progesterone and breast cancer. Womens Health (Lond.) 4 (2008), 151–162.
17. [17] Dowsett, M., Nielsen, T.O., A'Hern, R., Bartlett, J., Coombes, R.C., Cuzick, J., Ellis, M., Henry, N.L., Hugh, J.C., Lively, T., McShane, L., Paik, S., Penault-Llorca, F., Prudkin, L., Regan, M., Salter, J., Sotiriou, C., Smith, I.E., Viale, G., Zujewski, J.A., Hayes, D.F., Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J. Natl. Cancer Inst. 103 (2011), 1656–1664.
18. [18] Yerushalmi, R., Woods, R., Ravdin, P.M., Hayes, M.M., Gelmon, K.A., Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11 (2010), 174–183.
19. [19] Forbes, D., Blom, H., Kostomitsopoulos, N., Moore, G., Perretta, G., Felasa Euroguide on the accommodation and care of animals used for experimental and other scientific purposes. R. Soc. Med. Lond., 2007.
20. [20] Russo, J., Russo, I.H., Atlas and histologic classification of tumors of the rat mammary gland. J. Mammary Gland Biol. Neoplasia 5 (2000), 187–200.
21. [21] Hammond, M.E., Hayes, D.F., Dowsett, M., Allred, D.C., Hagerty, K.L., Badve, S., Fitzgibbons, P.L., Francis, G., Goldstein, N.S., Hayes, M., Hicks, D.G., Lester, S., Love, R., Mangu, P.B., McShane, L., Miller, K., Osborne, C.K., Paik, S., Perlmutter, J., Rhodes, A., Sasano, H., Schwartz, J.N., Sweep, F.C.G., Taube, S., Torlakovic, E.E., Valenstein, P., Viale, G., Visscher, D., Wheeler, T., Williams, R.B., Wittliff, J.L., Wolff, A.C., American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28 (2010), 2784–2795.
22. [22] Kang, J.S., Jung, N.J., Kim, S., Kim, D.J., Jang, D.D., Yang, K.H., Downregulation of estrogen receptor alpha and beta expression in carcinogen-induced mammary gland tumors of rats. Exp. Oncol. 26 (2004), 31–35.
23. [23] Russo, J., Significance of rat mammary tumors for human risk assessment. Toxicol. Pathol. 43 (2015), 145–170.
24. [24] Shirai, K., Uemura, Y., Fukumoto, M., Tsukamoto, T., Pascual, R., Nandi, S., Tsubura, A., Synergistic effect of MNU and DMBA in mammary carcinogenesis and H-ras activation in female Sprague-Dawley rats. Cancer Lett. 120 (1997), 87–93.
25. [25] Thordarson, G., Lee, A.V., McCarty, M., Van, H.K., Chu, O., Chou, Y.C., Yang, J., Guzman, R.C., Nandi, S., Talamantes, F., Growth and characterization of N-methyl-N-nitrosourea-induced mammary tumors in intact and ovariectomized rats. Carcinogenesis 22 (2001), 2039–2047.
26. [26] Boopalan, T., Arumugam, A., Parada, J., Saltzstein, E., Lakshmanaswamy, R., Receptor activator for nuclear factor-kappaB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis. Cancer Sci. 106 (2015), 25–33.
27. [27] Kariagina, A., Xie, J., Langohr, I.M., Opreanu, R.C., Basson, M.D., Haslam, S.Z., Progesterone stimulates proliferation and promotes cytoplasmic localization of the cell cycle inhibitor p27 in steroid receptor positive breast cancers. Horm. Cancer 4 (2013), 381–390.
28. [28] Bae, S.Y., Kim, S., Lee, J.H., Lee, H.C., Lee, S.K., Kil, W.H., Kim, S.W., Lee, J.E., Nam, S.J., Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer, 15, 2015, 138.
29. [29] Morgan, D.A., Refalo, N.A., Cheung, K.L., Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy. Breast 20 (2011), 215–219.
30. [30] Ren, Z., Li, Y., Shen, T., Hameed, O., Siegal, G.P., Wei, S., Prognostic factors in advanced breast cancer: race and receptor status are significant after development of metastasis. Pathol. Res. Pract. 212 (2016), 24–30.
31. [31] Vici, P., Pizzuti, L., Natoli, C., Gamucci, T., Di, L.L., Barba, M., Sergi, D., Botti, C., Michelotti, A., Moscetti, L., Mariani, L., Izzo, F., D'Onofrio, L., Sperduti, I., Conti, F., Rossi, V., Cassano, A., Maugeri-Sacca, M., Mottolese, M., Marchetti, P., Triple positive breast cancer: a distinct subtype?. Cancer Treat. Rev. 41 (2015), 69–76.